BLT2, a leukotriene B(4) receptor 2, as a novel prognostic biomarker of triple-negative breast cancer

Triple-negative breast cancer (TNBC) is considered to be a notorious type of cancer due to its aggressive metastatic potential and poor prognosis. Recent evidence suggests that BLT2, a low-affinity LTB(4) receptor is critically associated with the phenotypes of TNBC cells, including invasion, metast...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, JaeIn, Jang, Jae-Hyun, Park, Geun-Soo, Chung, Yunro, You, Hye Jin, Kim, Jae-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Biochemistry and Molecular Biology 2018
Materias:
Invited Mini Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6130834/
https://www.ncbi.nlm.nih.gov/pubmed/29898809
http://dx.doi.org/10.5483/BMBRep.2018.51.8.127
Descripción
Sumario:Triple-negative breast cancer (TNBC) is considered to be a notorious type of cancer due to its aggressive metastatic potential and poor prognosis. Recent evidence suggests that BLT2, a low-affinity LTB(4) receptor is critically associated with the phenotypes of TNBC cells, including invasion, metastasis, and survival. Furthermore, in a group of 545 breast cancer patients with metastasis, we observed that the high-BLT2 subgroup had a lower disease-free-survival rate than the low-BLT2 subgroup. Thus, we theorized that anti-BLT2 strategies could facilitate the development of new therapies used for TNBC. This review focuses on recent discoveries regarding BLT2 and its roles in as a novel prognostic biomarker in TNBC.

Ejemplares similares